Compare Aehr Test Systems (AEHR) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aehr Test Systems vs Sanofi SA — how do they compare? Aehr Test Systems trades at $129.2 (market cap $3.82B), while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 27.3× Aehr Test Systems's market cap, and Sanofi SA pays a 5.55% dividend while Aehr Test Systems pays none. Which is the better fit depends on your goals.
| AEHR | SNY | |
|---|---|---|
Market Cap | $3.82B | $104.30B |
Sector | Technology | Health |
52-Week High | $117.18 | $52.34 |
52-Week Low | $17.38 | $41.33 |
Enterprise Value | $3.72B | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEHR Test Systems (AEHR) surged 25.02% to $132.77, driven by strong earnings beats and a $22 million follow-on order for AI processor wafer-level burn-in systems (Accesswire, August 12, 2026). The stock exhibits bullish technical signals with support at $112 and resistance at $129, though RSI suggests overbought conditions. Revenue reached $58.97 million in 2025, but net income remained negative at -$3.91 million, reflecting high growth investments.
Outlook is optimistic due to AI and silicon photonics demand, with FY27 revenue growth projected at 160–200% (Seeking Alpha, July 18, 2026). Risks include customer concentration and negative cash flow. Analysts are mixed (33% buy, 67% hold), highlighting valuation concerns at a P/S of 71.87. Upside potential exists if execution aligns with backlog growth.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aehr Test Systems
Aehr Test Systems provides testing and burn-in solutions for the semiconductor industry. Its systems ensure the reliability of AI processors, data center chips, and electric vehicle components at the wafer and package levels.
Read more on AEHR →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
